All In Biotech

Drug Trial Radar · NCT04354246

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

94

Actual

Start

Mar 31, 2020

Primary completion

Apr 1, 2026

Study completion Apr 1, 2026

Sponsor

Lead sponsor
Compugen LtdIndustry
Sponsor type
Industry
First posted
Apr 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.

Conditions

  • Advanced Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Colon Cancer
  • Plasma Cell Neoplasm
  • Multiple Myeloma
  • HNSCC
  • Microsatellite Stable Colorectal Carcinoma
  • MSS-CRC

Interventions

  • Dose escalation: COM902 monotherapy.Drug

    COM902 monotherapy administered IV every 3 weeks in sequential dose escalation doses in cohorts of subjects.

  • Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)Combination product

    Both study drugs will be evaluated at the RDFE for assessment of safety and tolerability. All study drugs will be administered IV every 3 weeks.

  • Cohort expansion: COM902 (RDFE) monotherapy.Drug

    COM902 monotherapy (RDFE) in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.

  • Cohort expansion: COM902 in combination with COM701 (both at the RDFE).Drug

    COM902 in combination with COM701 (both at RDFE) in subjects with select tumor types who have exhausted standard treatment - HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.

  • Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.Combination product

    Triplet combination of COM902 + COM701 + Pembrolizumab administered IV every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The safety and tolerability of COM902 monotherapy and in combination with COM701.Time frame: DLT evaluation window in the 1st cycle (21 Days).
  2. To identify the maximum tolerated dose (MTD) and/or recommended dose for expansion of COM902 monotherapy and in combination with COM701.Time frame: 18 months.
  3. To characterize the pharmacokinetic (PK) profile of COM902 as monotherapy and in combination with COM701.Time frame: 18 months.
  4. Evaluation of safety and tolerability of the Triplet combination (COM902 + COM701 + Pembrolizumab).Time frame: 18 months.
  5. Evaluation of the PK profile of the Triplet combination (COM902 + COM701 + Pembrolizumab).Time frame: 18 months.
  6. Evaluation of the PK profile of the Triplet combination (COM902 + COM701 + Pembrolizumab).Time frame: 18 months.

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Florida Cancer Specialists

    Sarasota, Florida

  • Massachusetts General Hospital.

    Boston, Massachusetts

  • START Midwest.

    Grand Rapids, Michigan

  • The Ohio State University Comprehensive Cancer Center.

    Columbus, Ohio

  • The University of Tennessee WEST Cancer Center.

    Memphis, Tennessee

  • Mary Crowley Cancer Research

    Dallas, Texas

  • MD Anderson Cancer Center.

    Houston, Texas

  • The START Center for Cancer Care.

    San Antonio, Texas

  • Froedtert & Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.